Ultragenyx Pharmaceuticals Announces First Patient Enrolled In Phase 2 Study Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome
3/11/2014 8:03:00 AM
Novato, CA, March 11, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient enrolled in the Phase 2 study of triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS), at Columbia University. Glut1 DS, also known as De Vivo disease, is a rare, severely debilitating disease characterized by seizures, developmental delay, and movement disorder. - See more at: http://www.globenewswire.com/news-release/2014/03/11/617396/10072064/en/Ultragenyx-Announces-First-Patient-Enrolled-in-Phase-2-Study-of-Triheptanoin-in-Glucose-Transporter-Type-1-Deficiency-Syndrome.html#sthash.ORaFUasA.dpuf
Help employers find you! Check out all the jobs and post your resume.
comments powered by